SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Cilt: 50 Sayı: 3

MATRIX METALLOPROTEINASE INHIBITORS WITH ANTICANCER ACTIVITY

ANTİKANSER ETKİLİ MATRİKS METALLOPROTEİNAZ ENZİM İNHİBİTÖRLERİ

Zehra Arslan(ANKARA ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ, FARMASOTİK KİMYA ANABİLİM DALI)0000-0001-9169-667X
Oya Bozdağ Dündar(ANKARA ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ, FARMASOTİK KİMYA ANABİLİM DALI)0000-0002-2240-8854
Pages
834–859
Publication Date
2026-09-19
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, protein engineering approaches, antibody-based inhibitors, and biological agents such as TIMPs and pro-domain-like molecules represent next-generation strategies that enhance selectivity and biocompatibility.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To provide up-to-date information on the structure, function, and specific activities of matrix metalloproteinases (MMPs), with particular emphasis on gelatinases MMP-2 and MMP-9 as anticancer therapeutic targets due to their roles in cancer development, angiogenesis, tumor invasion, and metastasis.
📊
Key Findings & Data:Additionally, this review evaluates the design, development, and selectivity strategies of gelatinase inhibitors, focusing primarily on synthetic MMP inhibitors.
💡
Conclusion & Impact:Furthermore, protein engineering approaches, antibody-based inhibitors, and biological agents such as TIMPs and pro-domain-like molecules represent next-generation strategies that enhance selectivity and biocompatibility.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antikanser aktivite · çinko (II) bağlama grubu · hidroksamik asit

Abstract

Objective: To provide up-to-date information on the structure, function, and specific activities of matrix metalloproteinases (MMPs), with particular emphasis on gelatinases MMP-2 and MMP-9 as anticancer therapeutic targets due to their roles in cancer development, angiogenesis, tumor invasion, and metastasis. Additionally, this review evaluates the design, development, and selectivity strategies of gelatinase inhibitors, focusing primarily on synthetic MMP inhibitors. Result and Discussion: MMPs are enzymes belonging to the metalloproteinase family that participate in numerous physiological and pathological processes, including tissue remodeling, wound healing, and angiogenesis, by degrading structural components of the extracellular matrix. The overexpression of gelatinases MMP-2 and MMP-9 in various malignancies has rendered these enzymes significant therapeutic targets. First-generation MMP inhibitors consisted of compounds bearing zinc-binding groups (ZBGs), such as hydroxamic acid, thiol, carboxylate, phosphonate, or nitrogen-containing heterocyclic structures. Hydroxamate-based inhibitors emerged as prominent candidates in early studies due to their strong zinc-chelating properties and broad-spectrum activity; however, clinical limitations, including lack of selectivity and musculoskeletal toxicity, have driven the development of alternative approaches, such as ZBG-free inhibitors and mechanism-based or allosteric inhibition strategies. Structural studies have revealed the critical role of the S1′ subsite in determining selectivity, thereby guiding the rational design of narrow-spectrum, gelatinase-selective inhibitors. Furthermore, protein engineering approaches, antibody-based inhibitors, and biological agents such as TIMPs and pro-domain-like molecules represent next-generation strategies that enhance selectivity and biocompatibility.

Özet

Amaç: Matriks metalloproteinazların (MMP’ler) yapısı, işlevi ve özgül aktiviteleri hakkında güncel bilgileri sunmak; özellikle MMP-2 ve MMP-9 olarak bilinen jelatinazların kanser gelişimi, anjiyogenez, tümör invazyonu ve metastaz oluşturmadaki rolleri doğrultusunda antikanser terapötik hedefler olarak önemini vurgulamaktır. Ayrıca, sentetik MMP inhibitörleri başta olmak üzere jelatinaz inhibitörlerinin tasarımı, geliştirilmesi ve seçicilik stratejilerinin değerlendirilmesi amaçlanmıştır. Sonuç ve Tartışma: MMP’ler, hücre dışı matriksin yapısal bileşenlerini parçalayarak doku yeniden şekillenmesi, yara iyileşmesi ve anjiyogenez gibi birçok fizyolojik ve patolojik süreçte rol oynayan metalloproteinazlar ailesine ait enzimlerdir. Jelatinazlar olarak sınıflandırılan MMP-2 ve MMP-9’un çeşitli malignitelerde aşırı ekspresyon göstermesi, bu enzimleri önemli terapötik hedefler haline getirmiştir. İlk kuşak MMP inhibitörleri; hidroksamik asit, tiyol, karboksilat, fosfonat veya azot içeren heterosiklik yapılarda çinko bağlayıcı gruplar (ZBG) taşıyan bileşiklerden oluşmuştur. Hidroksamat bazlı inhibitörler güçlü çinko şelatlama özellikleri ve geniş spektrumlu etkileriyle öne çıkmış; ancak seçicilik eksikliği ve kas-iskelet sistemi toksisitesi gibi klinik sınırlamalar, ZBG içermeyen inhibitörler ile mekanizma temelli ve allosterik inhibisyon yaklaşımlarının geliştirilmesini teşvik etmiştir. Yapısal çalışmalar, özellikle S1′ alt cebinin seçiciliğin belirlenmesindeki kilit rolünü ortaya koymuş ve jelatinazlara özgü dar spektrumlu inhibitörlerin rasyonel tasarımına yön vermiştir. Ayrıca protein mühendisliği, antikor temelli inhibitörler ile TIMP ve pro-domain benzeri biyolojik ajanlar, seçiciliği ve biyouyumluluğu artıran yeni nesil yaklaşımlar arasında yer almaktadır.

🔖

Cite This Article

Arslan, Z., Dündar, O. B. (2026). MATRIX METALLOPROTEINASE INHIBITORS WITH ANTICANCER ACTIVITY. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 50 Sayı: 3, 834–859. https://doi.org/10.33483/jfpau.1736844

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (102)

  1. Cui, N., Hu, M., Khalil, R.A. (2017). Chapter One - Biochemical and Biological Attributes of Matrix Metalloproteinases. Eds: Khalil R.A. Progress in Molecular Biology and Translational Science, Elsevier Academic Press Inc, California, 1-73.
  2. Klein, T., Bischoff, R. (2010). Physiology and pathophysiology of matrix metalloproteases. Amino Acids, 41(2), 271-290. [CrossRef]
  3. Trabocchi, A., Lenci, E. (2024). Matrix Metalloproteases. Eds: Supuran, C.T., Donald, W.A. Metalloenzymes, Academic Press, Amsterdam, 197-206.
  4. Maskos, K. (2005). Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie, 87, 249-263. [CrossRef]
  5. Amalinei, C., Căruntu, I.D., Giuşcă, S.E., Balan, R.A. (2017). Complex Mechanisms of Matrix Metalloproteinases Involvement in Endometrial Physiology and Pathology-An Update. Eds: Chakraborti, S., Chakraborti, T., Dhalla, N. Proteases in Human Diseases, Springer, Singapore, 41-67.
  6. Schechter, I., Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochemical and Biophysical Research Communications, 27(2), 157-162. [CrossRef]
  7. Bode, W., Reinemer, P., Huber, R., et al. (1994). The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. The European Molecular Biology Organization Journal, 13(6), 1263-1269. [CrossRef]
  8. Fischer, T., Senn, N., Riedl, R. (2019). Design and structural evolution of matrix metalloproteinase ınhibitors. Chemistry – A European Journal, 25(34), 7960-7980. [CrossRef]
  9. Visse, R., Nagase, H. (2003). Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Circulation Research, 92(8), 827-839. [CrossRef]
  10. Kwan, J.A., Schulze, C.J., Wang, W., et al. (2004). Matrix metalloproteinase‐2 (MMP‐2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP‐ribose) polymerase (PARP) in vitro. The Federation of American Societies for Experimental Biology Journal, 18(6), 690-692. [CrossRef]
  11. Murphy, G., Nagase, H. (2008). Progress in matrix metalloproteinase research. Molecular Aspects of Medicine, 29(5), 290-308. [CrossRef]
  12. Das, S., Amin, S.A., Jha, T. (2021). Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. European Journal of Medicinal Chemistry, 223, 113623. [CrossRef]
  13. Van Wart, H.E., Birkedal-Hansen, H. (1990). The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National Academy of Sciences, 87(14), 5578-5582. [CrossRef]
  14. Gimeno, A., Beltrán-Debón, R., Mulero, M., et al. (2020). Understanding the variability of the S1′ pocket to improve matrix metalloproteinase inhibitor selectivity profiles. Drug Discovery Today, 25(1), 38-57. [CrossRef]
  15. Daniele, A., Abbate, I., Oakley, C., et al. (2016). Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: A review. The International Journal Of Biochemistry and Cell Biology, 77, 91-101. [CrossRef]
  16. Patel, S., Sadhu, P., Kumari, M., et al. (2023). A review on anticancer agents: Conventional drugs and novel target specific inhibitors. Oriental Journal of Chemistry, 39(3), 657-669. [CrossRef]
  17. Fields, G.B. (2019). The rebirth of matrix metalloproteinase inhibitors: Moving beyond the dogma. Cells, 8(9), 984. [CrossRef]
  18. Mondal, S., Adhikari, N., Banerjee, S., et al. (2020). Corrigendum to “matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. European Journal of Medicinal Chemistry, 205, 112260. [CrossRef]
  19. Fields, G.B. (2019). Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases. Frontiers in Immunology, 10(6), 442290. [CrossRef]
  20. Almutairi, S., Kalloush, H.M., Manoon, N.A., et al. (2023). Matrix metalloproteinases inhibitors in cancer treatment: An updated review (2013-2023). Molecules, 28(14), 5567. [CrossRef]
  21. Mustafa, S., Koran, S., AlOmair, L. (2022). Insights into the role of matrix metalloproteinases in cancer and its various therapeutic aspects: A Review. Frontiers in Molecular Biosciences, 9, 896099. [CrossRef]
  22. Willenbrock, F., Murphy, G., Phillips, I.R., et al. (1995). The second zinc atom in the matrix metalloproteinase catalytic domain is absent in the full‐length enzymes: A possible role for the C‐terminal domain. Federation of European Biochemical Societies Letters, 358(2), 189-192. [CrossRef]
  23. Higashi, S., Miyazaki, K. (2008). Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by β-Amyloid precursor protein-derived inhibitor. Journal of Biological Chemistry, 283(15), 10068-10078. [CrossRef]
  24. Agrawal, A., Romero‐Perez, D., Jacobsen, J.A., et al. (2008). Zinc‐binding groups modulate selective inhibition of MMPs. ChemMedChem, 3(5), 812-820. [CrossRef]
  25. Jacobsen, J.A., Major Jourden, J.L., Miller, M.T., et al. (2010). To bind zinc or not to bind zinc: An examination of innovative approaches to improved metalloproteinase inhibition. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1803(1), 72-94. [CrossRef]
  26. Verma, R.P. (2012). Hydroxamic Acids as Matrix Metalloproteinase Inhibitors. Eds: Gupta, S. Matrix Metalloproteinase Inhibitors. Experientia Supplementum, 103, Springer, Basel, 137-176.
  27. Thompson, E.W., Reich, R., Martin, G.R., Albini, A. (1988). Factors Regulation Basement Membrane Invasion by Tumor Cells. Eds: Lippman, M.E., Dickson, R.B. Breast Cancer: Cellular and Molecular Biology. Cancer Treatment and Research, 40, Springer, Boston, MA, 239-249. [CrossRef]
  28. Jobin, P.G., Butler, G.S., Overall, C.M. (2017). New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1864(11), 2043-2055. [CrossRef]
  29. Igarashi, N., Kubota, T., Otani, Y., et al. (1999). Preventive effect of matrix metalloproteinase inhibitor, r‐94138, in combination with mitomycin c or cisplatin on peritoneal dissemination of human gastric cancer cell line tmk‐1 in nude mice. Japanese Journal of Cancer Research, 90(1), 116-121. [CrossRef]
  30. Conradi, R.A., Hilgers, A.R., Ho, N.F.H., et al. (1991). The influence of peptide structure on transport across Caco-2 cells. Pharmaceutical Research, 08(12), 1453-1460. [CrossRef]
  31. Aureli, L., Gioia, M., Cerbara, I., et al. (2008). Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Current Medicinal Chemistry, 15(22), 2192-2222. [CrossRef]
  32. Brown, P.D. (1998). Matrix metalloproteinase inhibitors. Breast Cancer Research and Treatment, 52(1-3), 125-136. [CrossRef]
  33. Moroy, G., Denhez, C., El Mourabit, H., et al. (2007). Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies. Bioorganic and Medicinal Chemistry, 15(14), 4753-4766. [CrossRef]
  34. Levin, J.I., Du, M.T., DiJoseph, J.F., et al. (2001). The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position. Bioorganic and Medicinal Chemistry Letters, 11(2), 235-238. [CrossRef]
  35. Macpherson, L.J. (1997). ChemInform abstract: Discovery of CGS 27023A, a non‐peptidic, potent, and orally active stromelysin ınhibitor that blocks cartilage degradation in rabbits. ChemInform, 28(48). [CrossRef]
  36. Jain, P., Saravanan, C., Singh, S.K. (2013). Sulphonamides: Deserving class as MMP inhibitors? European Journal of Medicinal Chemistry, 60, 89-100. [CrossRef]
  37. Wagner, S., Faust, A., Breyholz, H.J., et al. (2011). The MMP inhibitor (R)-2-(N-benzyl-4-(2-[18F] fluoroethoxy) phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. Applied Radiation and Isotopes, 69(6), 862-868. [CrossRef]
  38. Baidya, S.K., Amin, S.A., Jha, T. (2021). Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present. European Journal of Medicinal Chemistry, 213, 113044.[CrossRef]
  39. Hande, K.R., Collier, M., Paradiso, L., et al. (2004). Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Clinical Cancer Research, 10(3), 909-915. [CrossRef]
  40. Hugenberg, V., Behrends, M., Wagner, S., et al. (2018). Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid. EJNMMI Radiopharmacy and Chemistry, 3, 10. [CrossRef]
  41. Zapico, J.M., Puckowska, A., Filipiak, K., et al. (2015). Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family. Organic and Biomolecular Chemistry, 13(1), 142-156. [CrossRef]
  42. Nuti, E., Cantelmo, A.R., Gallo, C., et al. (2015). N-O-isopropyl sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors: Hit selection and in vivo antiangiogenic activity. Journal of Medicinal Chemistry, 58(18), 7224-7240. [CrossRef]
  43. Sjøli, S., Nuti, E., Camodeca, C., et al. (2016). Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors. European Journal of Medicinal Chemistry, 108, 141-153. [CrossRef]
  44. Barta, E., Becker, T.P., Bedell, D.J., et al. (2000). Synthesis and activity of selective MMP inhibitors with an aryl backbone. Bioorganic and Medicinal Chemistry Letters, 10(24), 2815-2817. [CrossRef]
  45. Bolelli, E., Bolelli T. (2020). Pharmacophore modeling studies on known MMP-9 enzyme inhibitors to identify the important common features. Journal of Faculty of Pharmacy of Ankara University, 44(2), 204-210. [CrossRef]
  46. Muri, E., Nieto, M., Sindelar, R., et al. (2012). Hydroxamic acids as pharmacological agents. Current Medicinal Chemistry, 9(17), 1631-1653. [CrossRef]
  47. Cerofolini, L., Fragai, M., Luchinat, C. (2019). Mechanism and inhibition of matrix metalloproteinases. Current Medicinal Chemistry, 26(15), 2609-2633. [CrossRef]
  48. Hu, J., Van den Steen, P.E., Sang, Q.X.A., et al. (2007). Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature Reviews Drug Discovery, 6(6), 480-498. [CrossRef]
  49. Mehner, C., Hockla, A., Miller, E., et al. (2014). Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget, 5(9), 2736-2749. [CrossRef]
  50. Baxter, A.D., Bird, J., Bhogal, R., et al. (1997) A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders. Bioorganic and Medicinal Chemistry Letters, 7(7), 897-902. [CrossRef]
  51. Whittaker, M., Floyd, C.D., Brown, P., et al. (1999). Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical Reviews, 99(9), 2735-2776. [CrossRef]
  52. Georgiadis, D., Yiotakis, A. (2008). Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge. Bioorganic and Medicinal Chemistry, 16(19), 8781-8794. [CrossRef]
  53. Fray, M.J., Dickinson, R.P., Huggins, J.P., et al. (2003). A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. Journal of Medicinal Chemistry, 46(16), 3514-3525. [CrossRef]
  54. Nozaki, S., Sissons, S., Chien, D.S., et al. (2003). Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model. Clinical and Experimental Metastasis, 20(5), 407-412. [CrossRef]
  55. Adhikari, N., Halder, A.K., Mallick, S., et al. (2016). Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. Bioorganic and Medicinal Chemistry, 24(18), 4291-4309. [CrossRef]
  56. Reiter, L.A., (1999). Cheminform abstract: Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket. ChemInform, 30(19). [CrossRef]
  57. Pochetti, G., Gavuzzo, E., Campestre, C., et al. (2006). Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. Journal of Medicinal Chemistry, 49(3), 923-931. [CrossRef]
  58. Arun, M.Z., Reel, B., Sala-Newby, G.B., et al. (2016). Zoledronate upregulates MMP-9 and -13 in rat vascular smooth muscle cells by inducing oxidative stress. Drug Design, Development and Therapy, 10, 1453-1460. [CrossRef]
  59. Cheng M., De B., Pikul S., et al. (2000). Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. Journal of Medicinal Chemistry, 43(3), 369-80. [CrossRef]
  60. Grams, F., Brandstetter, H., DAlò, S., et al. (2001). Pyrimidine-2,4,6-triones: A new effective and selective class of matrix metalloproteinase inhibitors. Biological Chemistry, 382(8). 1277-1285. [CrossRef]
  61. Breyholz, H.J., Schäfers, M., Wagner, S., et al. (2005). C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging. Journal of Medicinal Chemistry, 48(9), 3400-3409. [CrossRef]
  62. Wang, J., Medina, C., Radomski, M.W., et al. (2011). N-substituted homopiperazine barbiturates as gelatinase inhibitors. Bioorganic and Medicinal Chemistry, 19(16), 4985-4999. [CrossRef]
  63. Ayoup, M.S., Fouad, M.A., Abdel-Hamid, H., et al. (2020). Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis. European Journal of Medicinal Chemistry, 186, 111875. [CrossRef]
  64. Acharya, M.R., Venitz, J., Figg, W.D., et al. (2004). Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resistance Updates, 7(3), 195-208. [CrossRef]
  65. Hanemaaijer, R., van Lent N., Sorsa T., Salo T., Konttinen Y.T., Lindeman J. (2001). Inhibition of Matrix Metalloproteinases (MMPs) by Tetracyclines. Eds: Nelson, M., Hillen, W., Greenwald, R.A. Tetracyclines in Biology, Chemistry and Medicine, Birkhäuser, Basel, 267-281.
  66. Fisher, J.F., Mobashery, S. (2010). Mechanism-based profiling of MMPs. Methods in Molecular Biology, 622, 471. [CrossRef]
  67. Ikejiri, M., Bernardo, M.M., Bonfil, R.D., et al. (2005). Potent mechanism-based inhibitors for matrix metalloproteinases. Journal of Biological Chemistry, 280(40), 33992-34002. [CrossRef]
  68. Forbes, C., Shi, Q., Fisher, J.F., et al. (2009). Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases. Chemical Biology and Drug Design, 74(6), 527-534. [CrossRef]
  69. Gooyit, M., Suckow, M.A., Schroeder, V.A., et al. (2012). Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier. ACS Chemical Neuroscience, 3(10), 730-736. [CrossRef]
  70. Dufour, A., Sampson, N.S., Li, J., et al. (2011). Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Research, 71(14), 4977-4988. [CrossRef]
  71. Engel, C.K., Pirard, B., Schimanski, S., et al. (2005). Structural basis for the highly selective inhibition of MMP-13. Chemistry and Biology, 12(2), 181-189. [CrossRef]
  72. Nguyen, Y.T., Kim, N., Lee, H.J. (2023). Metal complexes as promising matrix metalloproteinases regulators. International Journal of Molecular Sciences, 24(2), 1258. [CrossRef]
  73. Palermo, G., Magistrato, A., Riedel, T., et al. (2015). Fighting cancer with transition metal complexes: From naked DNA to protein and chromatin targeting strategies. ChemMedChem, 11(12), 1199-1210. [CrossRef]
  74. Stefàno, E., Muscella, A., Benedetti, M., et al. (2022). Antitumor and antimigration effects of a new Pt compound on neuroblastoma cells. Biochemical Pharmacology, 202, 115124. [CrossRef]
  75. Merlino, A. (2016). Interactions between proteins and Ru compounds of medicinal interest: A structural perspective. Coordination Chemistry Reviews, 326, 111-134. [CrossRef]
  76. Mazuryk, O., Suzenet, F., Kieda, C., et al. (2015). The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells. Metallomics, 7(3), 553-566. [CrossRef]
  77. Elie, B.T., Fernández-Gallardo, J., Curado, N., et al. (2019). Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer. European Journal of Medicinal Chemistry, 161, 310-322. [CrossRef]
  78. Wang, J., Chen, D., Li, B., et al. (2016). Fe-MIL-101 exhibits selective cytotoxicity and inhibition of angiogenesis in ovarian cancer cells via downregulation of MMP. Scientific Reports, 6(1), 1-13. [CrossRef]
  79. Ruiz, M.C., Perelmulter, K., Levín, P., et al. (2022). Antiproliferative activity of two copper (II) complexes on colorectal cancer cell models: Impact on ROS production, apoptosis induction and NF-κB inhibition. European Journal of Pharmaceutical Sciences, 169, 106092. [CrossRef]
  80. Li, K., Tay, F.R., Yiu, C.K.Y. (2020). The past, present and future perspectives of matrix metalloproteinase inhibitors. Pharmacology and Therapeutics, 207, 107465. [CrossRef]
  81. Sela-Passwell, N., Rosenblum, G., Shoham, T., et al. (2010). Structural and functional bases for allosteric control of MMP activities: Can it pave the path for selective inhibition? Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1803(1), 29-38. [CrossRef]
  82. Scannevin, R.H., Alexander, R., Haarlander, T.M., et al. (2017). Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation. The Journal of Biological Chemistry, 292(43), 17963-17974. [CrossRef]
  83. Fray, M.J., Dickinson, R.P. (2001). Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorganic and Medicinal Chemistry Letters, 11(4), 571-574. [CrossRef]
  84. Chen, Y., Cohen, S.M. (2015). Investigating the selectivity of metalloenzyme inhibitors in the presence of competing metalloproteins. ChemMedChem, 10(10), 1733-1738. [CrossRef]
  85. Chakrabarti, A., Oehme, I., Witt, O., et al. (2015). HDAC8: A multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences, 36(7), 481-492. [CrossRef]
  86. Amin, S.A., Adhikari, N., Jha, T. (2017). Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? Pharmacological Research, 122, 8-19. [CrossRef]
  87. Cheng, X.C., Wang, R.L., Dong, Z.K., et al. (2012). Design, synthesis and evaluation of novel metalloproteinase inhibitors based on L-tyrosine scaffold. Bioorganic and Medicinal Chemistry, 20(19), 5738-5744. [CrossRef]
  88. Halder, A.K., Mallick, S., Shikha, D., et al. (2015). Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity. RSC Advances, 5, (88), 72373-72386. [CrossRef]
  89. Wang, L., Li, X., Zhang, S., et al. (2012). Natural products as a gold mine for selective matrix metalloproteinases inhibitors. Bioorganic and Medicinal Chemistry, 20(13), 4164-4171. [CrossRef]
  90. Mukherjee, P.K., Maity, N., Nema, N.K., Sarkar, B.K. (2013) Natural Matrix Metalloproteinase Inhibitors: Leads from Herbal Resources. Eds: Rahman, A. Studies in Natural Products Chemistry, Elsevier, Amsterdam, 91-113.
  91. Li, W., Saji, S., Sato, F., et al. (2013). Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects. The International Journal of Biological Markers, 28(2), 117-130. [CrossRef]
  92. Naponelli, V., Piscazzi, A., Mangieri, D. (2025). Cellular and molecular mechanisms modulated by genistein in cancer. International Journal of Molecular Sciences, 26(3), 1114. [CrossRef]
  93. Kasravi, M., Yaghoobi, A., Tayebi, T., et al. (2024). MMP inhibition as a novel strategy for extracellular matrix preservation during whole liver decellularization. Biomaterials Advances, 156, 213710. [CrossRef]
  94. Devy, L., Dransfield, D.T. (2011). New strategies for the next generation of matrix-metalloproteinase ınhibitors: Selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochemistry Research International, 2011, 1-11. [CrossRef]
  95. Fischer, T., Riedl, R. (2019). Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules, 24(12), 2265. [CrossRef]
  96. Marshall, D.C., Lyman, S.K., McCauley, S., et al. (2015). Selective allosteric ınhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLOS ONE, 10(5), e0127063. [CrossRef]
  97. Allen, J.L., Hames, R.A., Mastroianni, N.M., et al. (2022). Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an anti-invasive therapeutic in head and neck squamous cell carcinoma. Oral Oncology, 132, 106008. [CrossRef]
  98. Brew, K., Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochimica et Biophysica Acta, 1803(1), 55. [CrossRef]
  99. Grossman, M., Tworowski, D., Dym, O., et al. (2010). The intrinsic protein flexibility of endogenous protease inhibitor TMP-1 controls its binding interface and affects its function. Biochemistry, 49(29), 6184-6192. [CrossRef]
  100. Liu, J., Khalil, R.A. (2017). Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Progress in Molecular Biology and Translational Science, 148, 355-420. [CrossRef]
  101. Fingelton, B. (2008). MMPs as therapeutic targets-Still a viable option? Seminars in Cell and Developmental Biology, 19(1), 61-68. [CrossRef]
  102. Rangasamy, L., Di Geronimo, B., Ortín, I., et al. (2019). Molecular imaging probes based on matrix metalloproteinase inhibitors (MMPIs). Molecules, 24(16), 2982. [CrossRef]